JP2010510784A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010510784A5 JP2010510784A5 JP2009538639A JP2009538639A JP2010510784A5 JP 2010510784 A5 JP2010510784 A5 JP 2010510784A5 JP 2009538639 A JP2009538639 A JP 2009538639A JP 2009538639 A JP2009538639 A JP 2009538639A JP 2010510784 A5 JP2010510784 A5 JP 2010510784A5
- Authority
- JP
- Japan
- Prior art keywords
- her3
- receptor
- antibody
- sample
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 26
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 26
- 238000000034 method Methods 0.000 claims 17
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 102000005962 receptors Human genes 0.000 claims 8
- 108020003175 receptors Proteins 0.000 claims 8
- 230000026731 phosphorylation Effects 0.000 claims 7
- 238000006366 phosphorylation reaction Methods 0.000 claims 7
- 230000000694 effects Effects 0.000 claims 6
- 210000001519 tissue Anatomy 0.000 claims 6
- 230000014509 gene expression Effects 0.000 claims 5
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 5
- 230000004913 activation Effects 0.000 claims 4
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 claims 3
- 102000001301 EGF receptor Human genes 0.000 claims 3
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 claims 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 3
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 claims 3
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 claims 3
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 claims 3
- 238000005276 aerator Methods 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 230000004043 responsiveness Effects 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 230000002018 overexpression Effects 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010061968 Gastric neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000003780 hair follicle Anatomy 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86124306P | 2006-11-28 | 2006-11-28 | |
| EP06024658 | 2006-11-28 | ||
| US60/861,243 | 2006-11-28 | ||
| EP06024658.4 | 2006-11-28 | ||
| PCT/EP2007/010335 WO2008064884A1 (en) | 2006-11-28 | 2007-11-28 | Activated her3 as a marker for predicting therapeutic efficacy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010510784A JP2010510784A (ja) | 2010-04-08 |
| JP2010510784A5 true JP2010510784A5 (enExample) | 2011-01-20 |
| JP5656406B2 JP5656406B2 (ja) | 2015-01-21 |
Family
ID=38961070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009538639A Active JP5656406B2 (ja) | 2006-11-28 | 2007-11-28 | 治療効力を予測するためのマーカーとしての活性化ｈｅｒ３ |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20100047829A1 (enExample) |
| EP (2) | EP2518508A1 (enExample) |
| JP (1) | JP5656406B2 (enExample) |
| AU (1) | AU2007324868B2 (enExample) |
| CA (1) | CA2670522C (enExample) |
| WO (1) | WO2008064884A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011008990A1 (en) | 2009-07-15 | 2011-01-20 | Prometheus Laboratories Inc. | Drug selection for gastric cancer therapy using antibody-based arrays |
| BRPI0717416A2 (pt) | 2006-09-21 | 2013-11-12 | Prometheus Lab Inc | Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo |
| HRP20131113T1 (hr) | 2007-02-16 | 2014-01-17 | Merrimack Pharmaceuticals, Inc. | Protutijela protiv erbb3 i njihova uporaba |
| PE20090681A1 (es) | 2007-03-02 | 2009-06-10 | Genentech Inc | Prediccion de respuesta a un inhibidor her |
| BRPI0813583A2 (pt) | 2007-07-13 | 2014-12-30 | Prometheus Lab Inc | Métodos para selecionar um medicamento anticâncer, para identificar a resposta de um tumor pulmonar, e para prognosticar a resposta de um paciente, e, arranjo |
| CN103399144B (zh) | 2008-02-25 | 2015-10-28 | 雀巢产品技术援助有限公司 | 用抗体阵列选择乳腺癌治疗药物 |
| EP2138511A1 (en) * | 2008-06-27 | 2009-12-30 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | HER3 as a determinant for the prognosis of melanoma |
| BRPI0917871A2 (pt) | 2008-08-15 | 2017-06-20 | Merrimack Pharmaceuticals Inc | agente terapêutico anti-erbb3 para uso em terapia de um tumor, métodos para predizer responsividade de um tumor de um agente terapêutco anti-erbb3, para selecionar terapia anti-erbb3 para um paciente, para predizer a resposta de células ao tratamento com um agente terapêutico, para identificar um biomarcador, e para evitar administração de uma droga para câncer anti-erbb3, e, kit para predizer a resposta das células ao tratamento com um agente terapêutico |
| EP2352851A1 (en) | 2008-11-12 | 2011-08-10 | The United States Of America, As Represented By The Secretary, Department of Health and Human Services | Use of erbb4 as a prognostic and therapeutic marker for melanoma |
| US20120270745A1 (en) * | 2009-07-15 | 2012-10-25 | Prometheus Laboratories Inc. | Drug selection for cancer therapy by profiling signal transduction proteins in ascites or pleural efflux samples |
| DK2516469T3 (en) | 2009-12-22 | 2016-05-02 | Roche Glycart Ag | ANTI-HER3 antibodies and uses thereof |
| JP2013522237A (ja) | 2010-03-11 | 2013-06-13 | メリマック ファーマシューティカルズ インコーポレーティッド | トリプルネガティブおよび基底様乳癌の治療におけるｅｒｂｂ３阻害剤の使用 |
| US20110318336A1 (en) * | 2010-03-29 | 2011-12-29 | George Mason Intellectual Properties, Inc. | Identification and Treatment of Aggressive Lung Cancer Tumors |
| UY33498A (es) | 2010-07-09 | 2013-01-03 | Sanofi Aventis | Combinaciones de inhibidores de quinasas para el tratamiento de cancer |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| US9719995B2 (en) | 2011-02-03 | 2017-08-01 | Pierian Holdings, Inc. | Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling |
| WO2013033623A1 (en) | 2011-09-02 | 2013-03-07 | Nestec S.A. | Profiling of signal pathway proteins to determine therapeutic efficacy |
| AU2012318567B2 (en) * | 2011-10-04 | 2018-02-22 | Expression Pathology, Inc. | SRM/MRM assay for the receptor tyrosine-protein kinase erbB-4 protein (HER4) |
| MX350957B (es) | 2011-11-23 | 2017-09-27 | Medimmune Llc | Moleculas de union especificas para her3 y usos de las mismas. |
| AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
| KR101524915B1 (ko) | 2013-05-10 | 2015-06-02 | 포항공과대학교 산학협력단 | 타이로신 인산화효소를 감지하는 형광 프로브 및 이의 용도 |
| WO2015048008A2 (en) | 2013-09-24 | 2015-04-02 | Medimmune, Llc | Binding molecules specific for her3 and uses thereof |
| WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| WO2015157634A1 (en) | 2014-04-11 | 2015-10-15 | Kolltan Pharmaceuticals, Inc. | Anti-erbb antibodies and methods of use thereof |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5183884A (en) * | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| US5804396A (en) * | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| PT896586E (pt) | 1996-03-27 | 2007-01-31 | Genentech Inc | Anticorpos de erbb3 |
| US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
| AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
| US6277640B1 (en) * | 2000-07-31 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Antisense modulation of Her-3 expression |
| WO2002058450A2 (en) * | 2000-12-22 | 2002-08-01 | Dana-Faber Cancer Institute, Inc. | Regulation of cell growth by muc1 |
| US7125680B2 (en) * | 2001-07-27 | 2006-10-24 | The Regents Of The University Of California | Methods and materials for characterizing and modulating interaction between heregulin and HER3 |
| EP1283053A1 (en) * | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| US20040018528A1 (en) * | 2002-05-17 | 2004-01-29 | Sugen, Inc. | Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals |
| EP1803821B1 (en) * | 2002-06-05 | 2012-02-29 | Cedars-Sinai Medical Center | Methods for managing kinase inhibitor therapy |
| EP1540347B1 (en) | 2002-07-25 | 2009-09-09 | Aclara BioSciences, Inc. | Detecting receptor oligomerization |
| WO2004087887A2 (en) | 2003-04-01 | 2004-10-14 | Monogram Biosciences, Inc. | Intracellular complexes as biomarkers |
| KR101126560B1 (ko) * | 2003-05-30 | 2012-04-05 | 도꾜 다이가꾸 | 약제 반응 예측 방법 |
| JP2005024385A (ja) | 2003-07-02 | 2005-01-27 | Matsushita Electric Ind Co Ltd | 感圧センサ |
| US20060204966A1 (en) * | 2003-08-01 | 2006-09-14 | Spector Neil L | Treatment of cancers expressing p95 erbb2 |
| ES2553264T3 (es) * | 2004-05-27 | 2015-12-07 | The Regents Of The University Of Colorado | Métodos para la predicción del resultado clínico para inhibidores del receptor del factor de crecimiento epidérmico para pacientes de cáncer |
| AU2005314127A1 (en) * | 2004-12-07 | 2006-06-15 | Genentech, Inc. | Selecting patients for therapy with a HER inhibitor |
| TW200642695A (en) * | 2005-03-08 | 2006-12-16 | Genentech Inc | Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs) |
| AR056857A1 (es) * | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
-
2007
- 2007-11-28 EP EP12176507A patent/EP2518508A1/en not_active Withdrawn
- 2007-11-28 JP JP2009538639A patent/JP5656406B2/ja active Active
- 2007-11-28 US US12/516,682 patent/US20100047829A1/en not_active Abandoned
- 2007-11-28 EP EP07846863.4A patent/EP2097754B2/en active Active
- 2007-11-28 WO PCT/EP2007/010335 patent/WO2008064884A1/en not_active Ceased
- 2007-11-28 AU AU2007324868A patent/AU2007324868B2/en active Active
- 2007-11-28 CA CA2670522A patent/CA2670522C/en active Active
-
2016
- 2016-02-18 US US15/047,041 patent/US10365283B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010510784A5 (enExample) | ||
| Qian et al. | Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma | |
| JP5656406B2 (ja) | 治療効力を予測するためのマーカーとしての活性化ｈｅｒ３ | |
| Resnick et al. | Epidermal growth factor receptor, c-MET, β-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study | |
| Zhu et al. | Neuropilin-1 is overexpressed in osteosarcoma and contributes to tumor progression and poor prognosis | |
| WO2005010486A3 (en) | Biomarker panel for colorectal cancer | |
| JP2010539508A5 (enExample) | ||
| KR20140002711A (ko) | 항체-기반 어레이를 사용한 악성 암 치료를 위한 약물 선별법 | |
| Gadgeel | Personalized therapy of non-small cell lung cancer (NSCLC) | |
| Johnson et al. | Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma | |
| Ramsay et al. | Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy | |
| EP2817629A2 (en) | Elevated psma identifies lethal prostate cancers | |
| JP5413818B2 (ja) | 蛍光多重染色による蛋白定量法 | |
| Kossatz et al. | PARP1 as a biomarker for early detection and intraoperative tumor delineation in epithelial cancers–first-in-human results | |
| Bozzi et al. | Evidence for activation of KIT, PDGFRα, and PDGFRβ receptors in the Ewing sarcoma family of tumors | |
| JP2011527575A5 (enExample) | ||
| Rao et al. | Epigenetic markers in basal cell carcinoma: universal themes in oncogenesis and tumor stratification?-a short report | |
| Estévez et al. | Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ | |
| George | Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor | |
| CN103562722A (zh) | 一种区分甲状腺癌变的方法、实施该方法的试剂盒以及金属硫蛋白在区分甲状腺癌变中的用途 | |
| Sevinc et al. | The diagnosis of C-kit negative GIST by PDGFRA staining: clinical, pathological, and nuclear medicine perspective | |
| Cherciu et al. | Targeted Confocal Laser Endomicroscopy (CLE) for the Assessment of Putative Cancer Stem Cell Markers in Colorectal cancer-A Pilot Study | |
| JP7246731B2 (ja) | 膵癌の予後マーカー、膵癌の予後診断キット及び膵癌の予後を予測するための方法 | |
| Elliott et al. | A phase II single-arm, open-label trial of T-DM1 (ado-trastuzumab emtansine) And Neratinib for HER2 | |
| Murray et al. | HER2 activating mutations in estrogen receptor positive breast cancer |